ANT308 / Cambium Oncology - LARVOL DELTA

Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis. (PubMed, Cancer Lett) - "In vivo studies revealed that ANT308 treatment decreased MCAM expression in intraocular primary tumors, reduced the number and size of liver metastases following intraocular or subcutaneous melanoma injection, and showed a trend toward reduced tumor volume at the primary tumor site. In conclusion, our findings indicate that VIP receptor signaling promotes liver metastasis in melanoma, and targeting this pathway with VIP receptor antagonists may represent a novel therapeutic strategy for treating metastatic UVM."

Journal • Cutaneous Melanoma • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Pancreatic Cancer • Solid Tumor • Uveal Melanoma • CDH2 • MCAM

TARGETING VIP-RECEPTOR SIGNALING SELECTS A GUT MICROBIOME THAT SEPARATES GRAFT-VERSUS-LEUKEMIA (GVL) FROM GRAFT-VERSUS-HOST DISEASE (GVHD) IN ALLOGENEIC BONE MARROW TRANSPLANTATION (ALLO-BMT) (EBMT 2025) - "A potent peptide VIP-receptor antagonist (ANT308) was administered daily via subcutaneous injection for four weeks pre-transplant and/or four weeks post-transplant to evaluate its impact on microbiome composition and transplant outcomes... Microbiome transfer from VIP-KO mice to WT mice enhances anti-leukemic immunity, demonstrating the potential of a VIP-deficient microbiome to bolster tumor control. Pharmacologic inhibition of VIP signaling promotes microbiome shifts that mitigate GvHD while preserving GvL effects. These findings identify VIP-receptor signaling modulation as a promising strategy to separate GvHD from GvL, potentially improving outcomes in allo-BMT recipients."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation

Seeking Investors: First-in-Class Immunotherapeutics for Cancer (PRNewswire) - "Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, and the company observes no toxicity-limiting dosages. In addition to their Fast-Track SBIR NIH grant recently being funded for $2.4M, they have received a significant investment from OEP Innovations of Taiwan....MULTIPLE PROOFS-OF-CONCEPT - Leukemia and Pancreatic Cancers: (1)Leukemia: ANT308 has shown strong single-agent anti-leukemia activity in 2 mouse models. (2) Pancreatic cancer: ANT308 has shown synergistic effects with anti-PD-1 checkpoint inhibitors in 3 pancreatic cancer models."

Financing • Preclinical • Leukemia • Pancreatic Cancer

Novel Therapies for AML and other Cancers (PRNewswire) - "Cambium Oncology and Orient Euro Pharma (OEP) announce a strategic partnership in which OEP has invested $5M in Cambium Oncology. This will accelerate the clinical development of Cambium Oncology's lead therapeutic candidate, ANT308, a FIRST-IN-CLASS vasoactive intestinal peptide (VIP) receptor antagonist designed to restore anti-cancer T-cell function. This investment is in addition to $2.4M recently received from the NIH. PROOF-OF-CONCEPT: ANT308 has shown strong single-agent anti-leukemia activity in two AML mouse models and synergistic effects with anti-PD-1 checkpoint inhibitors in three pancreatic cancer (PDAC) models."

Licensing / partnership • Pancreatic Ductal Adenocarcinoma